drugset / Trial / NCT00357383

Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

NCT00357383

Phase 1 Completed Laboratoires Thea
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2). To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day treatment period

Timeline

Start
2002-10
Primary completion
Completion
2002-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 1 % Other
Subject Azithromycin Small molecule 1.5 % Other